BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wilson JM, Kunnimalaiyaan S, Kunnimalaiyaan M, Gamblin TC. Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis. Cancer Cell Int 2015;15:13. [PMID: 25674039 DOI: 10.1186/s12935-015-0161-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Han W, Cao F, Gao XJ, Wang HB, Chen F, Cai SJ, Zhang C, Hu YW, Ma J, Gu X, Ding HZ. ZIC1 acts a tumor suppressor in breast cancer by targeting survivin. Int J Oncol 2018;53:937-48. [PMID: 29956756 DOI: 10.3892/ijo.2018.4450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
2 Hu S, Chang X, Zhu H, Wang D, Chen G. PI3K mediates tumor necrosis factor induced-necroptosis through initiating RIP1-RIP3-MLKL signaling pathway activation. Cytokine 2020;129:155046. [PMID: 32114297 DOI: 10.1016/j.cyto.2020.155046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Mahipal A, Kommalapati A, Tella SH, Lim A, Kim R. Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opin Investig Drugs 2018;27:709-20. [PMID: 30124336 DOI: 10.1080/13543784.2018.1512581] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
4 Chiang NJ, Chen LT, Shan YS, Yeh CN, Chen MH. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules 2021;11:97. [PMID: 33451059 DOI: 10.3390/biom11010097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yang W, Sun Y. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. Onco Targets Ther 2021;14:1341-66. [PMID: 33658799 DOI: 10.2147/OTT.S297643] [Reference Citation Analysis]
6 Corti F, Nichetti F, Raimondi A, Niger M, Prinzi N, Torchio M, Tamborini E, Perrone F, Pruneri G, Di Bartolomeo M, de Braud F, Pusceddu S. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. Cancer Treat Rev 2019;72:45-55. [PMID: 30476750 DOI: 10.1016/j.ctrv.2018.11.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
7 Lee H, Ross JS. The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. Therap Adv Gastroenterol. 2017;10:507-520. [PMID: 28567120 DOI: 10.1177/1756283x17698090] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
8 Pastore M, Lori G, Gentilini A, Taddei ML, Di Maira G, Campani C, Recalcati S, Invernizzi P, Marra F, Raggi C. Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives. Cells 2020;9:E596. [PMID: 32138158 DOI: 10.3390/cells9030596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tessiri S, Techasen A, Kongpetch S, Namjan A, Loilome W, Chan-on W, Thanan R, Jusakul A. Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma. PeerJ 2022;10:e12750. [DOI: 10.7717/peerj.12750] [Reference Citation Analysis]
10 Jang DK, Lee YG, Chan Chae Y, Lee JK, Paik WH, Lee SH, Kim YT, Ryu JK. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway. Biochem Biophys Res Commun 2020;529:1242-8. [PMID: 32819590 DOI: 10.1016/j.bbrc.2020.06.011] [Reference Citation Analysis]
11 Kaavya J, Mahalaxmi I, Devi SM, Santhy KS, Balachandar V. Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route? J Cell Physiol 2019;234:8259-73. [PMID: 30370571 DOI: 10.1002/jcp.27673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Sokolowski KM, Balamurugan M, Kunnimalaiyaan S, Wilson J, Gamblin TC, Kunnimalaiyaan M. Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy. Am J Surg 2016;211:755-60. [PMID: 26850133 DOI: 10.1016/j.amjsurg.2015.11.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
13 Seeree P, Janvilisri T, Kangsamaksin T, Tohtong R, Kumkate S. Downregulation of ABCA1 and ABCG1 transporters by simvastatin in cholangiocarcinoma cells. Oncol Lett 2019;18:5173-84. [PMID: 31612028 DOI: 10.3892/ol.2019.10874] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Zou Y, Li X, Zhang Q, Liu D. RACK1 Silencing Induces Cell Apoptosis and Inhibits Cell Proliferation in Hepatocellular Carcinoma MHCC97-H Cells. Pathol Oncol Res 2018;24:101-7. [DOI: 10.1007/s12253-017-0214-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Daragmeh J, Barriah W, Saad B, Zaid H. Analysis of PI3K pathway components in human cancers. Oncol Lett 2016;11:2913-8. [PMID: 27073576 DOI: 10.3892/ol.2016.4309] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
16 Thongsom S, Suginta W, Lee KJ, Choe H, Talabnin C. Piperlongumine induces G2/M phase arrest and apoptosis in cholangiocarcinoma cells through the ROS-JNK-ERK signaling pathway. Apoptosis 2017;22:1473-84. [PMID: 28913568 DOI: 10.1007/s10495-017-1422-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
17 Shi CT, Ma J, Shi QF, Zhang Y, Wang HN. High Survivin and Low Zinc Finger of the Cerebellum 1 Expression Indicates Poor Prognosis in Triple-negative Breast Carcinoma. J Breast Cancer 2019;22:248-59. [PMID: 31281727 DOI: 10.4048/jbc.2019.22.e20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Yang J, Farren MR, Ahn D, Bekaii-Saab T, Lesinski GB. Signaling pathways as therapeutic targets in biliary tract cancer. Expert Opin Ther Targets 2017;21:485-98. [PMID: 28282502 DOI: 10.1080/14728222.2017.1306055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]